Cremerius U, Striepecke E, Henn W, Weis J, Mull M, Lippitz B, Gilsbach J, Schröder J M, Zang K D, Böcking A
Kliniken für Nuklearmedizin, RWTH Aachen, FRG.
Nuklearmedizin. 1994 Aug;33(4):144-9.
62 intracranial meningiomas in 60 patients were studied with 18FDG-PET prior to neurosurgery in order to evaluate the relationship between 18FDG uptake and biological aggressiveness of the tumors. Histopathological grading, cellular density, Ki-67 proliferation index and evidence of chromosomal aberrations were used to assess tumor aggressiveness. Significantly elevated 18FDG uptake was found in grade 2- and 3- compared to grade 1-meningiomas, in tumors of high cellularity compared with those of low cellularity, and in meningiomas with an elevated Ki-67 proliferation index (above 2%). The two meningiomas with the most pronounced chromosomal aberrations revealed the highest 18FDG uptake of all cytogenetically studied meningiomas. We conclude that 18FDG-PET is useful for estimating the biological aggressiveness of intracranial meningiomas.
为评估18F-FDG摄取与颅内脑膜瘤生物学侵袭性之间的关系,对60例患者的62个颅内脑膜瘤在神经外科手术前进行了18F-FDG-PET研究。采用组织病理学分级、细胞密度、Ki-67增殖指数和染色体畸变证据来评估肿瘤的侵袭性。与1级脑膜瘤相比,2级和3级脑膜瘤、高细胞密度肿瘤与低细胞密度肿瘤相比,以及Ki-67增殖指数升高(高于2%)的脑膜瘤中,18F-FDG摄取显著升高。在所有经细胞遗传学研究的脑膜瘤中,染色体畸变最明显的两个脑膜瘤显示出最高的18F-FDG摄取。我们得出结论:18F-FDG-PET有助于评估颅内脑膜瘤的生物学侵袭性。